Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Fresia Pareja, MD, PhD
Conference Coverage
Genomic Driven Artificial Intelligence Based System to Detect and Diagnose Lobular Carcinoma
01/05/2024
Fresia Pareja, MD, PhD, discussed novel mechanisms of CDH1 inactivation discovered using an artificial intelligence based system.
Fresia Pareja, MD, PhD, discussed novel mechanisms of CDH1 inactivation discovered using an artificial intelligence based system.
Fresia Pareja, MD, PhD,...
01/05/2024
Oncology
David Rimm, MD, PhD
Conference Coverage
Use of Quantitative Multiplex Immunofluorescence Assay to Detect TROP2 and HER2 Expression
01/05/2024
David Rimm, MD, PhD, discussed study results which identified quantitative multiplex immunofluorescence assay as an optimal way to detect TROP2 and HER2 expression in breast cancer.
David Rimm, MD, PhD, discussed study results which identified quantitative multiplex immunofluorescence assay as an optimal way to detect TROP2 and HER2 expression in breast cancer.
David Rimm, MD, PhD, discussed...
01/05/2024
Oncology
Hannah Cox, PhD, HCLD
Conference Coverage
Demographic, Germline Genetic Findings From Patients in Puerto Rico Based on Personal/Family History of Breast Cancer
01/04/2024
Hannah Cox, PhD, HCLD, discussed clinical findings from genetic analyses of Puerto Rican patients with a personal/family history of breast cancer.
Hannah Cox, PhD, HCLD, discussed clinical findings from genetic analyses of Puerto Rican patients with a personal/family history of breast cancer.
Hannah Cox, PhD, HCLD, discussed...
01/04/2024
Oncology
Hatem Azim, MD, PhD
Conference Coverage
Use of Fertility Preservation and Assisted Reproductive Technologies to Attempt Pregnancy Among Patients With Breast Cancer
01/04/2024
Hatem Azim, MD, PhD, discussed results from the POSITIVE trial.
Hatem Azim, MD, PhD, discussed results from the POSITIVE trial.
Hatem Azim, MD, PhD, discussed...
01/04/2024
Oncology
Seth Wander, MD, PhD
Conference Coverage
Vepdegestrant Plus Palbociclib for Patients With ER-Positive, HER2-Negative Advanced Breast Cancer
01/04/2024
Seth Wander, MD, PhD, discussed results from the phase 1b cohort of a phase 1/2 clinical trial, demonstrating that vepdegestrant plus palbociclib is clinically effective among patients with heavily pretreated, ER-positive, HER2-negative...
Seth Wander, MD, PhD, discussed results from the phase 1b cohort of a phase 1/2 clinical trial, demonstrating that vepdegestrant plus palbociclib is clinically effective among patients with heavily pretreated, ER-positive, HER2-negative...
Seth Wander, MD, PhD, discussed...
01/04/2024
Oncology
Lajos Pusztai, MD, DPhil
Conference Coverage
ctDNA Monitoring of Patients With ER-Positive, HER2-Negative High Risk Breast Cancer During Adjuvant Endocrine Therapy
01/03/2024
Lajos Pusztai, MD, DPhil, discussed results from the DARE study which analyzed the clinical utility of ctDNA monitoring during adjuvant endocrine therapy to detect molecular relapse before apparent recurrence.
Lajos Pusztai, MD, DPhil, discussed results from the DARE study which analyzed the clinical utility of ctDNA monitoring during adjuvant endocrine therapy to detect molecular relapse before apparent recurrence.
Lajos Pusztai, MD, DPhil,...
01/03/2024
Oncology
Akihiko Shimomura, MD
Conference Coverage
Trastuzumab, Pertuzumab, and Docetaxel Remains Standard of Care for Older Patients With HER2-Positive Metastatic Breast Cancer
01/03/2024
Akihiko Shimomura, MD, discussed results from a phase 3 study which compared trastuzumab emtansine against standard-of-care trastuzumab, pertuzumab, and docetaxel to determine optimal treatment for older patients with HER2-positive metastatic...
Akihiko Shimomura, MD, discussed results from a phase 3 study which compared trastuzumab emtansine against standard-of-care trastuzumab, pertuzumab, and docetaxel to determine optimal treatment for older patients with HER2-positive metastatic...
Akihiko Shimomura, MD, discussed...
01/03/2024
Oncology
Seema Khan, MD
Conference Coverage
Use of a 12-Gene DCIS Score to Guide Radiotherapy Decisions for Patients With Ductal Carcinoma in Situ
01/03/2024
Seema Khan, MD, discussed 5-year clinical outcomes from E4112 which identified that >90% of patients who underwent a 12-gene DCIS score to predict radiotherapy benefit followed DS-based recommendations.
Seema Khan, MD, discussed 5-year clinical outcomes from E4112 which identified that >90% of patients who underwent a 12-gene DCIS score to predict radiotherapy benefit followed DS-based recommendations.
Seema Khan, MD, discussed 5-year...
01/03/2024
Oncology
Rick Baehner, MD 
Conference Coverage
Individualization of Therapies for Patients With HR-Positive, HER2-Negative Breast Cancer
01/03/2024
Rick Baehner, MD, discussed results from the phase 3 ADAPTcycle trial.
Rick Baehner, MD, discussed results from the phase 3 ADAPTcycle trial.
Rick Baehner, MD, discussed...
01/03/2024
Oncology
Ana Ferrigno, MD
Conference Coverage
Maternal and Neonatal Safety of Taxane Chemotherapy During Pregnancy for the Treatment of Breast Cancer
12/28/2023
Ana Ferrigno, MD, discussed results from an international cohort study which demonstrated that the use of taxane-containing chemotherapy during pregnancy does not increase the risk of obstetric and neonatal complications.
Ana Ferrigno, MD, discussed results from an international cohort study which demonstrated that the use of taxane-containing chemotherapy during pregnancy does not increase the risk of obstetric and neonatal complications.
Ana Ferrigno, MD, discussed...
12/28/2023
Oncology
Eleftherios Mamounas, MD
Conference Coverage
Loco-Regional Irradiation for Patients With Biopsy-Proven Axillary Node Involvement Who Become Node-Negative After Neoadjuvant Chemotherapy
12/28/2023
Eleftherios Mamounas, MD, discussed primary results from the NRG Oncology/NSABP B-51/RTOG 1304 study.
Eleftherios Mamounas, MD, discussed primary results from the NRG Oncology/NSABP B-51/RTOG 1304 study.
Eleftherios Mamounas, MD,...
12/28/2023
Oncology
Anouk Hiensch, PhD 
Conference Coverage
Use of a Structured, Individualized Exercise Program for Patients With Metastatic Breast Cancer
12/28/2023
Anouk Hiensch, PhD, discussed results from the PREFERABLE-EFFECT study, which demonstrated that starting a structured, individualized exercise intervention during palliative treatment for metastatic breast cancer decreased fatigue and...
Anouk Hiensch, PhD, discussed results from the PREFERABLE-EFFECT study, which demonstrated that starting a structured, individualized exercise intervention during palliative treatment for metastatic breast cancer decreased fatigue and...
Anouk Hiensch, PhD, discussed...
12/28/2023
Oncology
Gurdeep S. Mannu, DPhil, FRSC
Conference Coverage
Long-Term Outcomes of Axillary Treatment in Early Breast Cancer
12/20/2023
Gurdeep S. Mannu, DPhil, FRCS, gave a comprehensive overview of axillary treatment for patients with early breast cancer.
Gurdeep S. Mannu, DPhil, FRCS, gave a comprehensive overview of axillary treatment for patients with early breast cancer.
Gurdeep S. Mannu, DPhil, FRCS,...
12/20/2023
Oncology
Amy Tiersten, MD
Conference Coverage
Front-Line Anastrozole, Palbociclib, Trastuzumab, and Pertuzumab for HR-Positive, HER2-Positive Metastatic Breast Cancer
12/19/2023
Amy Tiersten, MD, Mount Sinai, discussed results from the phase 1/2 ASPIRE study investigating combination anastrozole, palbociclib, trastuzumab, and pertuzumab for previously untreated patients with HR-positive, HER2-positive metastatic...
Amy Tiersten, MD, Mount Sinai, discussed results from the phase 1/2 ASPIRE study investigating combination anastrozole, palbociclib, trastuzumab, and pertuzumab for previously untreated patients with HR-positive, HER2-positive metastatic...
Amy Tiersten, MD, Mount Sinai,...
12/19/2023
Oncology
Oleg Gluz, MD, West German Study Group
Videos
Response to Short Preoperative Endocrine Therapy Among Patients With HR-Positive, HER2-Negative Breast Cancer
12/08/2023
Oleg Gluz, MD, shares results from the screening cohort of the phase 3 ADAPTcycle trial.
Oleg Gluz, MD, shares results from the screening cohort of the phase 3 ADAPTcycle trial.
Oleg Gluz, MD, shares results...
12/08/2023
Oncology
Conference Coverage
Addition of Zanidatamab to Standard Palbociclib Plus Fulvestrant Improved Survival, Response in HER2-Positive, HR-Positive, Metastatic Breast Cancer
12/08/2023
According to primary results from a phase 2a study, the addition of zanidatamab to standard palbociclib and fulvestrant demonstrated promising progression-free survival and durable response among patients with HER2-positive, hormone...
According to primary results from a phase 2a study, the addition of zanidatamab to standard palbociclib and fulvestrant demonstrated promising progression-free survival and durable response among patients with HER2-positive, hormone...
According to primary results...
12/08/2023
Oncology
John Robertson, MD chB BSc, MD, FRCS
Conference Coverage
Optimal Camizestrant Dose for Patients With ER-Positive, HER2-Negative Primary Breast Cancer
12/08/2023
John Robertson MB chB BSc, MD, FRCS, shared results from the SERENA-3 trial, investigating the effect multiple doses of camizestrant at different treatment durations has on ER, ki-67, and PgR expression.
John Robertson MB chB BSc, MD, FRCS, shared results from the SERENA-3 trial, investigating the effect multiple doses of camizestrant at different treatment durations has on ER, ki-67, and PgR expression.
John Robertson MB chB BSc, MD,...
12/08/2023
Oncology
News
No Benefit from Addition of Atezolizumab to Standard of Care Among Patients With HER2-Positive Breast Cancer
12/08/2023
According to results from a phase 3 trial, the addition of atezolizumab to chemotherapy plus trastuzumab and peruzumab did not increase the pathologic complete response among patients with HER2-positive breast cancer.
According to results from a phase 3 trial, the addition of atezolizumab to chemotherapy plus trastuzumab and peruzumab did not increase the pathologic complete response among patients with HER2-positive breast cancer.
According to results from a...
12/08/2023
Oncology
Peter Schmid, MD, PhD, Barts Cancer Center
Videos
Addition of Pembrolizumab to Neoadjuvant Chemotherapy Plus Adjuvant Pembrolizumab Improved EFS Among Patients with Early-Stage Triple-Negative Breast Cancer
12/08/2023
Peter Schmid, MD, PhD, presents updated results from the KEYNOTE-522 study, describing the benefit of adding pembrolizumab to neoadjuvant chemotherapy with adjuvant pembrolizumab in early-stage triple-negative breast cancer.
Peter Schmid, MD, PhD, presents updated results from the KEYNOTE-522 study, describing the benefit of adding pembrolizumab to neoadjuvant chemotherapy with adjuvant pembrolizumab in early-stage triple-negative breast cancer.
Peter Schmid, MD, PhD, presents...
12/08/2023
Oncology
News
Trastuzumab Emtansine Improved Survival Among Patients With Residual Invasive HER2-Positive Early Breast Cancer
12/08/2023
According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.
According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.
According to results from the...
12/08/2023
Oncology
Michail Ignatiadis, MD, PhD, Jules Bordet Institute
Videos
No Benefit From Addition of Atezolizumab to Adjuvant Chemotherapy Among Patients with Triple-Negative Breast Cancer
12/07/2023
Michail Ignatiadis, MD, PhD, discusses the interim analysis of a phase 3 trial which found adding atezolizumab to adjuvant chemotherapy was very unlikely to provide benefit to patients with triple-negative breast cancer.
Michail Ignatiadis, MD, PhD, discusses the interim analysis of a phase 3 trial which found adding atezolizumab to adjuvant chemotherapy was very unlikely to provide benefit to patients with triple-negative breast cancer.
Michail Ignatiadis, MD, PhD,...
12/07/2023
Oncology
Aditya Bardia, MD, MPH
Conference Coverage
Datopotamab Deruxtecan for Patients With Previously Treated, Inoperable, or Metastatic HR-Positive, HER2-Negative Breast Cancer
12/07/2023
Aditya Bardia, MD, MPH, discussed results from the TROPION-Breast01 trial comparing datopotamab deruxtecan, a TROP-2 directed antibody drug conjugate, with standard chemotherapy in endocrine-resistant metastatic breast cancer.
Aditya Bardia, MD, MPH, discussed results from the TROPION-Breast01 trial comparing datopotamab deruxtecan, a TROP-2 directed antibody drug conjugate, with standard chemotherapy in endocrine-resistant metastatic breast cancer.
Aditya Bardia, MD, MPH,...
12/07/2023
Oncology
Antonio Llombart-Cussac MD, PhD
Conference Coverage
Palbociclib Plus Fulvestrant or Letrozole for HR-Positive, HER2-Negative Advanced Breast Cancer
12/07/2023
Antonio Llombart-Cussac MD, PhD, discussed extended follow-up results from the phase 2 PARSIFAL study combining the CDK4/6 inhibitor palbociclib with either fulvestrant or letrozole.
Antonio Llombart-Cussac MD, PhD, discussed extended follow-up results from the phase 2 PARSIFAL study combining the CDK4/6 inhibitor palbociclib with either fulvestrant or letrozole.
Antonio Llombart-Cussac MD, PhD,...
12/07/2023
Oncology
Hongnan Mo, MD
Conference Coverage
Efficacy, Safety of Toripalimab Plus Metronomic Chemotherapy for HER2-Negative Metastatic Breast Cancer
12/07/2023
Hongnan Mo, MD, discussed results from a phase 2 study comparing metronomic chemotherapy plus PD-1 blockade to combined conventional chemotherapy plus immune checkpoint blockade.
Hongnan Mo, MD, discussed results from a phase 2 study comparing metronomic chemotherapy plus PD-1 blockade to combined conventional chemotherapy plus immune checkpoint blockade.
Hongnan Mo, MD, discussed...
12/07/2023
Oncology
Sara Hurvitz, MD, Fred Hutchinson Cancer Center
Videos
Tucatinib Plus Trastuzumab Emtansine Improved Progression-Free Survival Among Patients With HER2-Positive Metastatic Breast Cancer
12/06/2023
Sara Hurvitz, MD, shares results from the HER2CLIMB-02 trial evaluating tucatinib plus trastuzumab emtansine among patients with previously-treated HER2-positive metastatic breast cancer.
Sara Hurvitz, MD, shares results from the HER2CLIMB-02 trial evaluating tucatinib plus trastuzumab emtansine among patients with previously-treated HER2-positive metastatic breast cancer.
Sara Hurvitz, MD, shares results...
12/06/2023
Oncology
Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA
Videos
Genomic Differences Among HER2-Low, HER2-Zero, and HER2-Positive Breast Cancer
04/28/2023
Paolo Tarantino, MD, discusses advancements in genomic study and treatment efficacy for HER2-Low, HER2-Zero, and HER2-Positive breast cancers.
Paolo Tarantino, MD, discusses advancements in genomic study and treatment efficacy for HER2-Low, HER2-Zero, and HER2-Positive breast cancers.
Paolo Tarantino, MD, discusses...
04/28/2023
Oncology
Clinton Yam, MD, MD Anderson Cancer Center, Houston, TX
Videos
Characteristics of HER2-Low vs HER2-Zero Early-Stage Triple-Negative Breast Cancer
03/06/2023
At the 2022 San Antonio Breast Cancer Symposium, Clinton Yam, MD, discussed the clinical and molecular characteristics of HER2-low early-stage triple-negative breast cancer compared to HER2-zero early-stage triple-negative breast cancer.
At the 2022 San Antonio Breast Cancer Symposium, Clinton Yam, MD, discussed the clinical and molecular characteristics of HER2-low early-stage triple-negative breast cancer compared to HER2-zero early-stage triple-negative breast cancer.
At the 2022 San Antonio Breast...
03/06/2023
Oncology
Aditya Bardia, MD, Massachusetts General Hospital, Boston, MA
Videos
Neoadjuvant Trastuzumab Deruxtecan for HER2-Low, HR-Positive Breast Cancer
02/02/2023
At the 2022 San Antonio Breast Cancer Symposium, Aditya Bardia, MD, discusses the efficacy of neoadjuvant trastuzumab deruxtecan for patients with HER2 low, HR-positive early-stage breast cancer.
At the 2022 San Antonio Breast Cancer Symposium, Aditya Bardia, MD, discusses the efficacy of neoadjuvant trastuzumab deruxtecan for patients with HER2 low, HR-positive early-stage breast cancer.
At the 2022 San Antonio Breast...
02/02/2023
Oncology
Ruth O’Regan, MD, University of Rochester, NY
Videos
Breast Cancer Index Assay to Select for Ovarian Suppression in Premenopausal Women With HR-Positive Breast Cancer
01/31/2023
At the 2022 San Antonio Breast Cancer Symposium, Ruth O’Regan, MD, presented updated data from the SOFT trial, investigating the predictive potential of the breast cancer index assay in determining which premenopausal patients with...
At the 2022 San Antonio Breast Cancer Symposium, Ruth O’Regan, MD, presented updated data from the SOFT trial, investigating the predictive potential of the breast cancer index assay in determining which premenopausal patients with...
At the 2022 San Antonio Breast...
01/31/2023
Oncology
Arielle Medford, MD, Dana-Farber Cancer Institute, Boston, MA
Videos
Monitoring for Circulating Tumors DNA to Select for Adjuvant Therapy Escalation Among Patients With HR-Positive/HER2-Negative Breast Cancer
01/30/2023
At the 2022 San Antonio Breast Cancer Symposium, Arielle Medford, MD, discusses results from the ongoing LEADER trial, investigating the efficacy of adjuvant endocrine therapy plus CDK4/6 inhibitor ribociclib for HR-positive, HER2-negative...
At the 2022 San Antonio Breast Cancer Symposium, Arielle Medford, MD, discusses results from the ongoing LEADER trial, investigating the efficacy of adjuvant endocrine therapy plus CDK4/6 inhibitor ribociclib for HR-positive, HER2-negative...
At the 2022 San Antonio Breast...
01/30/2023
Oncology
Neelima Vidula, MD, Massachusetts General Hospital, Boston, MA
Videos
Talazoparib for Patients With Somatic BRCA-Mutant Metastatic Breast Cancer
01/26/2023
At the 2022 San Antonio Breast Cancer Symposium, Neelima Vidula, MD, discusses the ongoing phase 2 trial evaluating the efficacy of talazoparib for patients with BRCA-mutant, HER2-negative metastatic breast cancer.
At the 2022 San Antonio Breast Cancer Symposium, Neelima Vidula, MD, discusses the ongoing phase 2 trial evaluating the efficacy of talazoparib for patients with BRCA-mutant, HER2-negative metastatic breast cancer.
At the 2022 San Antonio Breast...
01/26/2023
Oncology
Cynthia Ma, MD, PhD, Washington University, St. Louis, MO
Videos
Selecting Neoadjuvant Therapy for HR-Positive Breast Cancer
01/26/2023
At the 2022 San Antonio Breast Cancer Symposium, Cynthia Ma, MD, PhD, discusses the neoadjuvant therapy options available for patients with HR-positive breast cancer.
At the 2022 San Antonio Breast Cancer Symposium, Cynthia Ma, MD, PhD, discusses the neoadjuvant therapy options available for patients with HR-positive breast cancer.
At the 2022 San Antonio Breast...
01/26/2023
Oncology
Ariella Hanker, PhD, UT Southwestern Medical Center, Dallas, TX
Videos
Biological Mechanisms of CDK4/6 Inhibitor Resistance
01/24/2023
At the 2022 San Antonio Breast Cancer Symposium, Ariella Hanker, PhD, discusses the biological mechanisms behind CDK4/6 inhibitor resistance and novel approaches being developed to overcome this resistance in patients with breast cancer.
At the 2022 San Antonio Breast Cancer Symposium, Ariella Hanker, PhD, discusses the biological mechanisms behind CDK4/6 inhibitor resistance and novel approaches being developed to overcome this resistance in patients with breast cancer.
At the 2022 San Antonio Breast...
01/24/2023
Oncology
Ruth O'Regan, MD, University of Rochester
Videos
Debate: Are All CDK4/6 Inhibitors the Same?
01/23/2023
At the 2022 San Antonio Breast Cancer Symposium, Ruth O'Regan, MD, participated in the debate, “Are All CDK4/6 Inhibitors the Same or Different?” in which she took the position that they are different.
At the 2022 San Antonio Breast Cancer Symposium, Ruth O'Regan, MD, participated in the debate, “Are All CDK4/6 Inhibitors the Same or Different?” in which she took the position that they are different.
At the 2022 San Antonio Breast...
01/23/2023
Oncology
Joanne Kotsopoulos, PhD, Women’s College Research Institute, Toronto, Ontario, Canada
Videos
Impact of Hormonal Exposures on Breast and Ovarian Cancer Risk Among BRCA1/2 Carriers
01/19/2023
At the 2022 San Antonio Breast Cancer Symposium, Joanne Kotsopoulos, PhD, discusses the risks certain hormonal exposures can pose for BRCA1/2 carriers.
At the 2022 San Antonio Breast Cancer Symposium, Joanne Kotsopoulos, PhD, discusses the risks certain hormonal exposures can pose for BRCA1/2 carriers.
At the 2022 San Antonio Breast...
01/19/2023
Oncology
Rachel Jimenez, MD, Massachusetts General Hospital
Videos
Advances in Radiotherapy for Patients With Breast Cancer
01/10/2023
At the 2022 San Antonio Breast Cancer Symposium, Rachel Jimenez, MD, reviews updates and advancements in radiotherapy technology for patients with breast cancer.
At the 2022 San Antonio Breast Cancer Symposium, Rachel Jimenez, MD, reviews updates and advancements in radiotherapy technology for patients with breast cancer.
At the 2022 San Antonio Breast...
01/10/2023
Oncology
Per Karlsson, MD, PhD, Sahlgrenska Comprehensive Cancer Center
Videos
Prognostic Value of the POLAR Scores for Radiotherapy Benefit Among Patients with HR-Positive, HER2-Negative Breast Cancer
01/10/2023
At the 2022 San Antonio Breast Cancer Symposium, Per Karlsson, MD, PhD presents results from the meta-analysis investigating the prognostic value of POLAR scores in predicting the benefit of radiotherapy for patients with breast cancer.
At the 2022 San Antonio Breast Cancer Symposium, Per Karlsson, MD, PhD presents results from the meta-analysis investigating the prognostic value of POLAR scores in predicting the benefit of radiotherapy for patients with breast cancer.
At the 2022 San Antonio Breast...
01/10/2023
Oncology
Aditya Bardia, MD, Mass General Cancer Center
Conference Coverage
Identifying Endocrine-Sensitive Disease in HR-Positive Metastatic Breast Cancer
01/10/2023
At the 2022 San Antonio Breast Cancer Symposium, Aditya Bardia, MD, discusses the efficacy of elacestrant vs standard of care endocrine therapy for patients with ER-positive, HER2-negative, metastatic breast cancer by duration of prior...
At the 2022 San Antonio Breast Cancer Symposium, Aditya Bardia, MD, discusses the efficacy of elacestrant vs standard of care endocrine therapy for patients with ER-positive, HER2-negative, metastatic breast cancer by duration of prior...
At the 2022 San Antonio Breast...
01/10/2023
Oncology
Rachel Jimenez, MD, Massachusetts General Hospital
Videos
Proton Therapy as a Radiation Option to Reduce Cardiac Toxicity in Breast Cancer
01/06/2023
Rachel Jimenez, MD, discusses an upcoming clinical trial examining the efficacy of advanced radiation technology in reducing radiation-related toxicity for patients with breast cancer.
Rachel Jimenez, MD, discusses an upcoming clinical trial examining the efficacy of advanced radiation technology in reducing radiation-related toxicity for patients with breast cancer.
Rachel Jimenez, MD, discusses an...
01/06/2023
Oncology
Sara Hurvitz, MD, David Geffen School of Medicine
Videos
Trastuzumab Deruxtecan for HR-Positive, HER2-Low, Early-Stage Breast Cancer
12/22/2022
At the 2022 San Antonio Breast Cancer Symposium, Sara Hurvitz, MD, presents preliminary results from the TRIO-US B-12 TALENT trial, investigating trastuzumab deruxtecan for patients with HR-positive, HER2-low, early-stage breast cancer.
At the 2022 San Antonio Breast Cancer Symposium, Sara Hurvitz, MD, presents preliminary results from the TRIO-US B-12 TALENT trial, investigating trastuzumab deruxtecan for patients with HR-positive, HER2-low, early-stage breast cancer.
At the 2022 San Antonio Breast...
12/22/2022
Oncology
Mafalda Oliviera, MD, PhD, Vall d'Hebron University Hospital
Videos
Camizestrant for ER-Positive, HER2-Negative, Metastatic Breast Cancer
12/21/2022
At the 2022 San Antonio Breast Cancer Symposium, Mafalda Oliviera, MD, PhD, discusses results from the SERENA-2 trial, investigating camizestrant for ER-positive, HER-2 negative, metastatic breast cancer that had progressed on endocrine...
At the 2022 San Antonio Breast Cancer Symposium, Mafalda Oliviera, MD, PhD, discusses results from the SERENA-2 trial, investigating camizestrant for ER-positive, HER-2 negative, metastatic breast cancer that had progressed on endocrine...
At the 2022 San Antonio Breast...
12/21/2022
Oncology
Seth Wander, MD, PhD, Massachusetts General Hospital
Videos
Genomic and Molecular Mechanisms of Resistance to CDK4/6 Inhibitors
12/21/2022
Seth Wander MD, PhD, discusses research presented at the 2022 San Antonio Breast Cancer Symposium, focusing on the genomic and molecular mechanisms of resistance to CDK4/6 inhibitors and antiestrogens in metastatic breast cancer.
Seth Wander MD, PhD, discusses research presented at the 2022 San Antonio Breast Cancer Symposium, focusing on the genomic and molecular mechanisms of resistance to CDK4/6 inhibitors and antiestrogens in metastatic breast cancer.
Seth Wander MD, PhD, discusses...
12/21/2022
Oncology
Matthew Goetz, MD, Mayo Clinic
Videos
Lasofoxifene for Targeting ESR1 Mutant in Breast Cancer After CDK4/6 Inhibition
12/21/2022
At the 2022 San Antonio Breast Cancer Symposium, Matthew Goetz, MD, discusses a translational end point from the ELAINE-1 trial, examining patient outcomes for HR-positive, HER2-negative breast cancer with an ESR1 mutation treated with...
At the 2022 San Antonio Breast Cancer Symposium, Matthew Goetz, MD, discusses a translational end point from the ELAINE-1 trial, examining patient outcomes for HR-positive, HER2-negative breast cancer with an ESR1 mutation treated with...
At the 2022 San Antonio Breast...
12/21/2022
Oncology
Erika Hamilton, MD, Sarah Cannon Research Institute
Videos
Trastuzumab Deruxtecan Plus Pertuzumab in the First-Line Setting for Patients With Metastatic HER2-Positive Breast Cancer
12/21/2022
Erika Hamilton reviews updated results from a trial investigating trastuzumab deruxtecan alone and in different combinations, notably with pertuzumab, in the first-line setting for patients with metastatic HER2-positive breast cancer.
Erika Hamilton reviews updated results from a trial investigating trastuzumab deruxtecan alone and in different combinations, notably with pertuzumab, in the first-line setting for patients with metastatic HER2-positive breast cancer.
Erika Hamilton reviews updated...
12/21/2022
Oncology
Joseph Sparano, MD, Tisch Cancer Institute
Videos
Efficacy of Endocrine Therapy Alone for Patients with ER-Positive, HER2-Negative Breast Cancer
12/20/2022
At the 2022 San Antonio Breast Cancer Symposium, Joseph Sparano, MD, discusses the efficacy of endocrine therapy alone for patients with ER-positive, HER2-negative, lymph node-negative breast cancer.
At the 2022 San Antonio Breast Cancer Symposium, Joseph Sparano, MD, discusses the efficacy of endocrine therapy alone for patients with ER-positive, HER2-negative, lymph node-negative breast cancer.
At the 2022 San Antonio Breast...
12/20/2022
Oncology
Conference Coverage
Endocrine Therapy Interruption to Pursue Pregnancy Does Not Affect Short-Term Recurrence Rates
12/09/2022
According to study results presented at the 2022 San Antonio Breast Cancer Symposium, patients with breast cancer who temporarily paused endocrine therapy to pursue pregnancy did not experience higher short-term recurrence rates.
According to study results presented at the 2022 San Antonio Breast Cancer Symposium, patients with breast cancer who temporarily paused endocrine therapy to pursue pregnancy did not experience higher short-term recurrence rates.
According to study results...
12/09/2022
Oncology
Aditya Bardia, MD, MPH, Mass General Cancer Center
Videos
Sacituzumab Govitecan Improves Survival Regardless of Trop-2 Expression Status for HR+, HER− Breast Cancer
12/09/2022
At the 2022 San Antonio Breast Cancer Symposium, Aditya Bardia, MD, MPH, shared results from the phase 3 TROPiCS-02 trial investigating sacituzumab govitecan vs physician choice of chemotherapy in previously treated patients with HR+/HER2−...
At the 2022 San Antonio Breast Cancer Symposium, Aditya Bardia, MD, MPH, shared results from the phase 3 TROPiCS-02 trial investigating sacituzumab govitecan vs physician choice of chemotherapy in previously treated patients with HR+/HER2−...
At the 2022 San Antonio Breast...
12/09/2022
Oncology
Virgina Kaklamani, MD, MD Anderson Cancer Center, Houston, Texas
Videos
Elacestrant Efficacy Associated With Duration of Prior CDK4/6 Inhibitor Treatment
12/09/2022
At the 2022 San Antonio Breast Cancer Symposium, Virgina Kaklamani, MD, discusses the impact of the duration of CDK4/6 inhibitor treatment on the efficacy of elacestrant for patients with metastatic ER-postiive, HER2-negative breast cancer.
At the 2022 San Antonio Breast Cancer Symposium, Virgina Kaklamani, MD, discusses the impact of the duration of CDK4/6 inhibitor treatment on the efficacy of elacestrant for patients with metastatic ER-postiive, HER2-negative breast cancer.
At the 2022 San Antonio Breast...
12/09/2022
Oncology
Mariana Chavez-MacGregor, MD, MD Anderson Cancer Center
Videos
No Improvement From Everolimus Added to Standard Endocrine Therapy for HR-Positive/HER2-Negative Breast Cancer
12/08/2022
Mariana Chavez-MacGregor, MD, shares results from the phase 3 SWOG S1207 trial, evaluating the addition of everolimus to standard endocrine therapy for patients with hormone receptor-positive, human epidermal growth factor 2-negative breast...
Mariana Chavez-MacGregor, MD, shares results from the phase 3 SWOG S1207 trial, evaluating the addition of everolimus to standard endocrine therapy for patients with hormone receptor-positive, human epidermal growth factor 2-negative breast...
Mariana Chavez-MacGregor, MD,...
12/08/2022
Oncology
Leif Ellisen, MD, PhD, Mass General Cancer Center
Videos
Understanding Mechanisms of Resistance to Antibody Drug Conjugates for Breast Cancers
12/08/2022
At the 2022 San Antonio Breast Cancer Symposium, Leif Ellisen, MD, PhD, presented an educational session on mechanisms of resistance to antibody drug conjugates.
At the 2022 San Antonio Breast Cancer Symposium, Leif Ellisen, MD, PhD, presented an educational session on mechanisms of resistance to antibody drug conjugates.
At the 2022 San Antonio Breast...
12/08/2022
Oncology
Sara Hurvitz, MD, David Geffen School of Medicine
Videos
Trastuzumab Deruxtecan Superior to T-DM1 in the Second-Line Setting for HER2-Positive Metastatic Breast Cancer
12/07/2022
Sara Hurvitz, MD, presents updated results from the phase 3 Destiny-Breast03 trial, comparing trastuzumab deruxtecan with trastuzumab emtansine in patients with HER2-positive metastatic breast cancer who progressed on first-line treatment.
Sara Hurvitz, MD, presents updated results from the phase 3 Destiny-Breast03 trial, comparing trastuzumab deruxtecan with trastuzumab emtansine in patients with HER2-positive metastatic breast cancer who progressed on first-line treatment.
Sara Hurvitz, MD, presents...
12/07/2022
Oncology
Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute
Videos
An Argument Against HER2 Low as a New Breast Cancer Subtype
12/07/2022
At the 2022 San Antonio Breast Cancer Symposium, Sara Tolaney, MD, MPH, makes the case that HER2 low should not be considered a new breast cancer subtype.
At the 2022 San Antonio Breast Cancer Symposium, Sara Tolaney, MD, MPH, makes the case that HER2 low should not be considered a new breast cancer subtype.
At the 2022 San Antonio Breast...
12/07/2022
Oncology
Conference Coverage
Adjuvant Abemaciclib Plus Endocrine Therapy Improved Survival Outcomes for Patients With High-Risk Early Breast Cancer
12/07/2022
Adding abemaciclib to endocrine therapy resulted in a meaningful increase of invasive disease-free survival and distant relapse-free survival for patients with HR-positive, HER2-negative, node-positive, high-risk early breast cancer,...
Adding abemaciclib to endocrine therapy resulted in a meaningful increase of invasive disease-free survival and distant relapse-free survival for patients with HR-positive, HER2-negative, node-positive, high-risk early breast cancer,...
Adding abemaciclib to endocrine...
12/07/2022
Oncology
Elisa Agostinetto, MD
Videos
Tackling Technical Assessment Challenges in HER2-Low BC Space
02/28/2022
In part 4 of this series, Elisa Agostinetto, MD, Institut Jules Bordet, discusses the challenges of technical assessment in the HER2-low breast cancer treatment space.
In part 4 of this series, Elisa Agostinetto, MD, Institut Jules Bordet, discusses the challenges of technical assessment in the HER2-low breast cancer treatment space.
In part 4 of this series, Elisa...
02/28/2022
Oncology
Dr Agostinetto
Videos
Future Developments in HER2-Low BC Featuring Dr Agostinetto
02/28/2022
In part three of this series, Dr Agostinetto, Institut Jules Bordet, highlights future trial developments in the HER2-low breast cancer space such as DESTINY-breast-04, DESTINY-breast-06, and DEBBRAH study.
In part three of this series, Dr Agostinetto, Institut Jules Bordet, highlights future trial developments in the HER2-low breast cancer space such as DESTINY-breast-04, DESTINY-breast-06, and DEBBRAH study.
In part three of this series, Dr...
02/28/2022
Oncology
Elisa Agostinetto, MD, Institut Jules Bordet
Videos
Promising New Therapies for HER2-Low Breast Cancer
02/28/2022
In part 2 of this series, Dr Agostinetto, Institut Jules Bordet, discusses several effective, promising agents in HER2-low breast cancer treatment.
In part 2 of this series, Dr Agostinetto, Institut Jules Bordet, discusses several effective, promising agents in HER2-low breast cancer treatment.
In part 2 of this series, Dr...
02/28/2022
Oncology
Dr Slavin
Podcasts
Dr Slavin Discusses Ways to Improve PRS by Reducing Ancestral Bias in BC
12/15/2021
Thomas Slavin, MD, reviews ways to improve polygenic risk scores (PRS) in breast cancer by reducing ancestral bias, presented at the 2021 San Antonio Breast Cancer Symposium.
Thomas Slavin, MD, reviews ways to improve polygenic risk scores (PRS) in breast cancer by reducing ancestral bias, presented at the 2021 San Antonio Breast Cancer Symposium.
Thomas Slavin, MD, reviews ways...
12/15/2021
Oncology
Sara Hurvitz, MD, Discusses Trials on Tucatinib Therapy for HER2+ Metastatic Breast Cancer
Videos
Sara Hurvitz, MD, Discusses Trials on Tucatinib Therapy for HER2+ Metastatic Breast Cancer
11/28/2021
Dr Hurvitz discusses the HER2CLIMB and HER2CLIMB-02 trials examining tucatinib's activity and safety in patients with HER2-positive metastatic breast cancer.
Dr Hurvitz discusses the HER2CLIMB and HER2CLIMB-02 trials examining tucatinib's activity and safety in patients with HER2-positive metastatic breast cancer.
Dr Hurvitz discusses the...
11/28/2021
Oncology
e
Conference Insider
Tucatinib Plus Letrozole, Palbociclib Active in HER2+ Breast Cancer
11/28/2021
Tucatinib plus letrozole and palbociclib was well-tolerated and active in patients with HR and HER2-positive metastatic breast cancer, according to interim data presented at the SABCS Annual Meeting.
Tucatinib plus letrozole and palbociclib was well-tolerated and active in patients with HR and HER2-positive metastatic breast cancer, according to interim data presented at the SABCS Annual Meeting.
Tucatinib plus letrozole and...
11/28/2021
Oncology
News
No Benefit Adding Ipatasertib to First-Line Paclitaxel for PIK3CA-Altered TNBC
11/27/2021
IPATunity130 trial data showed that adding ipatasertib to paclitaxel did not improve PFS in patients with PIK3CA/AKT1/PTEN-altered TNBC.
IPATunity130 trial data showed that adding ipatasertib to paclitaxel did not improve PFS in patients with PIK3CA/AKT1/PTEN-altered TNBC.
IPATunity130 trial data showed...
11/27/2021
Oncology
Hannah Linden, MD, Highlights AMEERA-1 Data for ER+/HER2- Metastatic Breast Cancer
Podcasts
Hannah Linden, MD, Highlights AMEERA-1 Data for ER+/HER2- Metastatic Breast Cancer
11/16/2021
Dr Linden shares encouraging results from the AMEERA-1 trial of SAR439859 for ER+/HER2- metastatic breast cancer, presented at the virtual SABCS Annual Meeting.
Dr Linden shares encouraging results from the AMEERA-1 trial of SAR439859 for ER+/HER2- metastatic breast cancer, presented at the virtual SABCS Annual Meeting.
Dr Linden shares encouraging...
11/16/2021
Oncology
Fractures and the Use of Bisphosphonates in Patients With Breast Cancer
Podcasts
Fractures and the Use of Bisphosphonates in Patients With Breast Cancer
11/03/2021
Julie Gralow, MD, Clinical Director at the Seattle Cancer Care Alliance, discusses findings from the SWOG S0307 trial.
Julie Gralow, MD, Clinical Director at the Seattle Cancer Care Alliance, discusses findings from the SWOG S0307 trial.
Julie Gralow, MD, Clinical...
11/03/2021
Oncology
Efficacy, Safety of Ribociclib Plus Letrozole for ER+/HER2- Breast Cancer
Videos
Efficacy, Safety of Ribociclib Plus Letrozole for ER+/HER2- Breast Cancer
11/28/2020
Mattea Reinisch, MD, highlights the final efficacy and safety results of the phase 3b, multi-center, open-label Ribecca trial for women with ER+, HER2- locally advanced or metastatic breast cancer, presented as a poster at the virtual SABCS...
Mattea Reinisch, MD, highlights the final efficacy and safety results of the phase 3b, multi-center, open-label Ribecca trial for women with ER+, HER2- locally advanced or metastatic breast cancer, presented as a poster at the virtual SABCS...
Mattea Reinisch, MD, highlights...
11/28/2020
Oncology
FES-PET Imaging Shows Promise in Detecting Metastatic Lobular Breast Cancer With Bone Metastases
Interview
FES-PET Imaging Shows Promise in Detecting Metastatic Lobular Breast Cancer With Bone Metastases
02/01/2020
Poorni Manohar, MD, discusses the promising potential of FES-PET imaging for detecting metastatic lobular breast cancer, especially with bone involvement.
Poorni Manohar, MD, discusses the promising potential of FES-PET imaging for detecting metastatic lobular breast cancer, especially with bone involvement.
Poorni Manohar, MD, discusses...
02/01/2020
Oncology
Improving Logistics to Encourage Patient Enrollment in Cancer Clinical Trials
Podcasts
Improving Logistics to Encourage Patient Enrollment in Cancer Clinical Trials
01/28/2020
Julie Gralow, MD, Clinical Director, Seattle Cancer Care Alliance, discusses ways that healthcare providers can encourage patient enrollment in cancer clinical trials.
Julie Gralow, MD, Clinical Director, Seattle Cancer Care Alliance, discusses ways that healthcare providers can encourage patient enrollment in cancer clinical trials.
Julie Gralow, MD, Clinical...
01/28/2020
Oncology
Scalp Cooling Device Lowers Risk for Chemo-Related Hair Loss, Gives Patients Control
Podcasts
Scalp Cooling Device Lowers Risk for Chemo-Related Hair Loss, Gives Patients Control
01/28/2020
Michelle Melisko, MD, discusses the background, benefits, and future potential of the DigniCap Scalp Cooling System.
Michelle Melisko, MD, discusses the background, benefits, and future potential of the DigniCap Scalp Cooling System.
Michelle Melisko, MD, discusses...
01/28/2020
Oncology
Identifying Bone Metastases in Metastatic Breast Cancer via FES and FDG PET Imaging
Interview
Identifying Bone Metastases in Metastatic Breast Cancer via FES and FDG PET Imaging
01/27/2020
Hannah Linden, MD, FACP, spoke about the use of FES and FDG PET imaging to identify bone metastases in patients with metastatic breast cancer.
Hannah Linden, MD, FACP, spoke about the use of FES and FDG PET imaging to identify bone metastases in patients with metastatic breast cancer.
Hannah Linden, MD, FACP, spoke...
01/27/2020
Oncology
Mark Pegram, MD, Discusses the HER2CLIMB Trial and Promising Nature of Tucatinib Therapy
Podcasts
Mark Pegram, MD, Discusses the HER2CLIMB Trial and Promising Nature of Tucatinib Therapy
01/10/2020
Dr Pegram spoke about the basis, findings, and clinical significance of the HER2CLIMB trial examining tucatinib therapy for HER2-positive breast cancer.
Dr Pegram spoke about the basis, findings, and clinical significance of the HER2CLIMB trial examining tucatinib therapy for HER2-positive breast cancer.
Dr Pegram spoke about the basis,...
01/10/2020
Oncology
DS-8201a Shows Promise in Treatment of HER2-Positive Breast Cancer
Podcasts
DS-8201a Shows Promise in Treatment of HER2-Positive Breast Cancer
01/01/2020
Sherene Loi, MD, PhD, speaks about the use of DS-8201a in the treatment of HER2-positive breast cancer.
Sherene Loi, MD, PhD, speaks about the use of DS-8201a in the treatment of HER2-positive breast cancer.
Sherene Loi, MD, PhD, speaks...
01/01/2020
Oncology
Podcasts
Effect of Cost on Adherence to Therapy in Patients With Breast Cancer
12/30/2019
Dawn Hershman, MD, MS, discusses how the cost of breast cancer treatment is directly tied to therapy adherence.
Dawn Hershman, MD, MS, discusses how the cost of breast cancer treatment is directly tied to therapy adherence.
Dawn Hershman, MD, MS, discusses...
12/30/2019
Oncology
Podcasts
Impact of Text Messaging on Therapy Adherence in Patients With Breast Cancer
12/28/2019
Julie Gralow, MD, Clinical Director at Seattle Cancer Care Alliance, talks about the clinical significance and findings of the SWOG S0307 trial.
Julie Gralow, MD, Clinical Director at Seattle Cancer Care Alliance, talks about the clinical significance and findings of the SWOG S0307 trial.
Julie Gralow, MD, Clinical...
12/28/2019
Oncology
Podcasts
Shanu Modi, MD, Discusses the DESTINY-Breast01 Trial
12/15/2019
Dr Modi discusses the basis, clinical significance, and findings of the DESTINY-Breast01 trial of DS-8201a therapy for HER2-low breast cancer.
Dr Modi discusses the basis, clinical significance, and findings of the DESTINY-Breast01 trial of DS-8201a therapy for HER2-low breast cancer.
Dr Modi discusses the basis,...
12/15/2019
Oncology
Podcasts
The Promising Role of Tucatinib in HER2-Positive Breast Cancer Therapy
12/11/2019
Sherene Loi MD, PhD, discusses the HER2CLIMB study and the promising role of tucatinib therapy.
Sherene Loi MD, PhD, discusses the HER2CLIMB study and the promising role of tucatinib therapy.
Sherene Loi MD, PhD, discusses...
12/11/2019
Oncology
News
Adding Capecitabine to Standard Adjuvant Chemo Improves DFS in Patients With TNBC
12/11/2019
According to study findings presented at SABCS 2019, combining capecitabine with standard adjuvant chemo significantly improved DFS rates in patients with TNBC.
According to study findings presented at SABCS 2019, combining capecitabine with standard adjuvant chemo significantly improved DFS rates in patients with TNBC.
According to study findings...
12/11/2019
Oncology
News
Trastuzumab Yields Fewer Toxicities Than Combo in Stage I, HER2-Positive Breast Cancer
12/11/2019
Adjuvant trastuzumab monotherapy led to significantly fewer clinically relevant toxicities than paclitaxel plus trastuzumab, according to study findings presented at SABCS 2019.
Adjuvant trastuzumab monotherapy led to significantly fewer clinically relevant toxicities than paclitaxel plus trastuzumab, according to study findings presented at SABCS 2019.
Adjuvant trastuzumab monotherapy...
12/11/2019
Oncology
Podcasts
Updates in the HER2 Breast Cancer Therapy Space - Part II
12/11/2019
Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the latest data being presented on HER2 breast cancer therapy options.
Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the latest data being presented on HER2 breast cancer therapy options.
Shanu Modi, MD, Memorial Sloan...
12/11/2019
Oncology
Podcasts
Reflecting on Advancements in the Treatment of HER2-Positive Breast Cancer
12/11/2019
Sherene Loi, MD, PhD, reflects on advances in the treatment landscape for HER2-positive breast cancer in the past 20 years.
Sherene Loi, MD, PhD, reflects on advances in the treatment landscape for HER2-positive breast cancer in the past 20 years.
Sherene Loi, MD, PhD, reflects...
12/11/2019
Oncology
Podcasts
Updates in the HER2 Breast Cancer Therapy Space - Part I
12/10/2019
Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the latest data being presented on HER2 breast cancer therapy options.
Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the latest data being presented on HER2 breast cancer therapy options.
Shanu Modi, MD, Memorial Sloan...
12/10/2019
Oncology
News
PIK3CA Mutation Testing Uncommon in Patients With Metastatic Breast Cancer
12/09/2019
Testing for PIK3CA mutations is uncommon in patients with HR-positive, HER2-negative, metastatic breast cancer, according to data being presented at SABCS 2019.
Testing for PIK3CA mutations is uncommon in patients with HR-positive, HER2-negative, metastatic breast cancer, according to data being presented at SABCS 2019.
Testing for PIK3CA mutations is...
12/09/2019
Oncology
News
Margetuximab Plus Chemo Improves PFS in HER2-Positive Metastatic Breast Cancer
12/09/2019
Data being presented at SABCS 2019 show that combining margetuximab with chemo improves PFS over trastuzumab in patients with treated HER2-positive metastatic breast cancer.
Data being presented at SABCS 2019 show that combining margetuximab with chemo improves PFS over trastuzumab in patients with treated HER2-positive metastatic breast cancer.
Data being presented at SABCS...
12/09/2019
Oncology
News
GDC-0077 Shows Promising Anti-Tumor Activity in PIK3CA-Mutant Breast Cancer
12/09/2019
Preliminary data being presented at SABCS 2019 demonstrate the promising anti-tumor activity of GDC-0077 in patients with PIK3CA-mutant breast cancer.
Preliminary data being presented at SABCS 2019 demonstrate the promising anti-tumor activity of GDC-0077 in patients with PIK3CA-mutant breast cancer.
Preliminary data being presented...
12/09/2019
Oncology
News
Assay Identifies Patients With Breast Cancer Who Could Benefit From PI3K Inhibitor Therapy
12/09/2019
Data being presented at SABCS 2019 suggest that measuring PI3K-involvement in the hyperactive S1P signaling of breast cancer cells can help identify patients who could benefit from PI3K inhibitor therapy.
Data being presented at SABCS 2019 suggest that measuring PI3K-involvement in the hyperactive S1P signaling of breast cancer cells can help identify patients who could benefit from PI3K inhibitor therapy.
Data being presented at SABCS...
12/09/2019
Oncology
Podcasts
Encouraging Clinical Trial Participation in Patients With Cancer
12/01/2019
Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the benefits of clinical trial participation for patients with cancer.
Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the benefits of clinical trial participation for patients with cancer.
Shanu Modi, MD, Memorial Sloan...
12/01/2019
Oncology
Podcasts
Treating Early Stage, HER2-Positive Breast Cancer
11/29/2019
Sherene Loi, MD, PhD, talks about how the treatment of early stage, HER2-positive breast cancer has evolved.
Sherene Loi, MD, PhD, talks about how the treatment of early stage, HER2-positive breast cancer has evolved.
Sherene Loi, MD, PhD, talks...
11/29/2019
Oncology

The annual San Antonio Breast Cancer Symposium offers researchers, healthcare providers, and those specializing in breast cancer care a forum for interaction, communication, and education.

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement